57 assets in Invasive Breast Carcinoma

Therapeutic assets addressing Invasive Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tamoxifen Invasive Breast Carcinoma	University of California, San Francisco	P4	BBB (75)
Letrozole Invasive Breast Carcinoma	Emory University	P4	BBB (74)
Anastrozole Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P4	BBB (72)
Exemestane Invasive Breast Carcinoma	University of California, San Francisco	P4	BBB (72)
Carboplatin Invasive Breast Carcinoma	Baylor Breast Care Center	P3	BB (68)
Fulvestrant Invasive Breast Carcinoma	Massachusetts General Hospital	P2	BB (68)
Trastuzumab Invasive Breast Carcinoma	Massachusetts General Hospital	P3	BB (68)
Pertuzumab Invasive Breast Carcinoma	Baylor Breast Care Center	P3	BB (67)
Capecitabine Invasive Breast Carcinoma	Dr. Tabassum Wadasadawala	P3	BB (66)
Cyclophosphamide Invasive Breast Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	BB (65)
Epirubicin Invasive Breast Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	BB (65)
Adriamycin Invasive Breast Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	BB (64)
Docetaxel Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P2	BB (64)
Eribulin Monomethanesulfonate Invasive Breast Carcinoma	National Cancer Institute (NCI)	P3	BB (64)
Metformin Invasive Breast Carcinoma	City of Hope Medical Center	P3	BB (64)
Pyrotinib Invasive Breast Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	BB (64)
Simvastatin Invasive Breast Carcinoma	Emory University	P2	BB (64)
Goserelin Invasive Breast Carcinoma	Atossa Therapeutics, Inc.	P3	B (63)
Trastuzumab Emtansine Invasive Breast Carcinoma	Massachusetts General Hospital	P3	B (63)
Tucatinib Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P3	B (63)
Atezolizumab Invasive Breast Carcinoma	Fondazione Michelangelo	P3	B (62)
Pembrolizumab Invasive Breast Carcinoma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	B (62)
Abemaciclib Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P2	B (60)
Cis-Diamminedichloroplatinum Ii Invasive Breast Carcinoma	ECOG-ACRIN Cancer Research Group	P3	B (60)
Trastuzumab Deruxtecan Invasive Breast Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Adebrelimab Invasive Breast Carcinoma	Zhejiang Cancer Hospital	P2	CCC (53)
Azacitidine Invasive Breast Carcinoma	University of Illinois at Chicago	P2	CCC (53)
Binimetinib Invasive Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (53)
Decitabine Invasive Breast Carcinoma	Virginia Commonwealth University	P2	CCC (53)
Durvalumab Invasive Breast Carcinoma	Filipa Lynce, MD	P2	CCC (53)
Fludeoxyglucose Invasive Breast Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fluzoparib Invasive Breast Carcinoma	Zhejiang Cancer Hospital	P2	CCC (53)
Hyaluronidase Zzxf Invasive Breast Carcinoma	Baylor Breast Care Center	P2	CCC (53)
Imlunestrant Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Invasive Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Invasive Breast Carcinoma	Medical College of Wisconsin	P2	CCC (53)
Ivuxolimab Invasive Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (53)
Ixabepilone Invasive Breast Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Neratinib Invasive Breast Carcinoma	Massachusetts General Hospital	P2	CCC (53)
Olaparib Invasive Breast Carcinoma	Beth Israel Deaconess Medical Center	P2	CCC (53)
Panitumumab Invasive Breast Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Rain-32 Invasive Breast Carcinoma	Rain Oncology Inc	P2	CCC (53)
Tart Cherry Invasive Breast Carcinoma	University of California, Davis	P2	CCC (53)
Z/E 4-Hydroxy Tamoxifen Invasive Breast Carcinoma	Northwestern University	P2	CCC (53)
Entinostat Invasive Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P1	CCC (51)
N-Desmethyl-4-Hydroxytamoxifen Invasive Breast Carcinoma	Atossa Therapeutics, Inc.	P2	CCC (51)
Utomilumab Invasive Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (50)
Avelumab Invasive Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (48)
Polo-Like Kinase 1 Inhibitor Nms-1286937 Invasive Breast Carcinoma	Antonio Giordano, MD	P1/2	CC (47)
Ribociclib Invasive Breast Carcinoma	Jonsson Comprehensive Cancer Center	P1/2	CC (47)

Showing 1 to 50 of 57 assets

PreviousPage 1 of 2Next